Abstract:Introduction: Fabry's disease is an X-linked lysosomal storage disorder caused by reduced activity of α-galactosidase A (GAL), leading to premature death on account of renal, cardiac, and vascular organ failure. Accumulation of the GAL substrate globotriaosylceramide (Gb3) in endothelial and smooth muscle cells is associated with early vascular cell damage, suggesting endothelial dysfunction as a driver of cardiorenal organ failure. Here, we studied the vascular expression of the key angiogenic factors, VEGFα and its antagonist angiostatin, in Fabry α-GAL-Tg/KO mice and determined circulating VEGFα and angiostatin serum levels in patients with Fabry's disease and healthy controls. Methods: Cryopreserved aortic vessels from six α-GAL-Tg/KO and six wild-type (WT) mice were obtained and VEGFα and angiostatin levels were determined by performing Western blot analysis. VEGFα expression was visualized by an immunohistochemical staining of paraffin aortic rings. In addition, VEGFα and angiostatin serum levels were measured by using an enzyme-linked immunosorbent assay in 48 patients with genetically verified Fabry's disease (50% male) and 22 healthy controls and correlated with disease severity markers such as lyso-Gb3, albuminuria, NTproBNP, high-sensitive troponin T (hsTNT), and myocardial wall thickness. Results: It was found that there was a significant increase in VEGFα protein expression (1.66 ± 0.35 vs. 0.62 ± 0.16, p = 0.0009) and a decrease in angiostatin expression (0.024 ± 0.007 vs. 0.053 ± 0.02, p = 0.038) in aortic lysates from α-GAL-Tg/KO compared with that from WT mice. Immunohistochemical staining revealed an adventitial VEGFα signal in α-GAL-Tg/KO mice, whereas no VEGFα signal could be detected in WT mice aortas. No differences in aortic angiostatin expression between α-GAL-Tg/KO- and WT mice could be visualized. The serum levels of VEGFα were significantly upregulated in patients with Fabry's disease compared with that in healthy controls (708.5 ± 426.3 vs. 458.5 ± 181.5 pg/ml, p = 0.048) and positively associated with albuminuria ( r = 0.82, p < 0.0001) and elevated NTproBNP ( r = 0.87, p < 0.0001) and hsTNT values ( r = 0.41, p = 0.048) in male patients with Fabry's disease. For angiostatin, no significant difference was found between patients with Fabry's disease and healthy controls (747.6 ± 390.3 vs. 858.8 ± 599.3 pg/ml). Discussion: In conclusion, an overexpression of VEGFα and downregulation of its counter player angiostatin in aortic tissue of α-GAL-Tg/KO mice support the hypothesis of an underlying vasculopathy in Fabry's disease. Elevated VEGFα serum levels were also observed in patients with Fabry's disease and were positively associated with elevated markers of organ manifestation in males. These findings suggest that angiogenetic markers, such as VEGFα, may be potentially useful biomarkers for the detection of endothelial dysfunction in classical Fabry's disease.

Vascular changes in Fabry disease

Clinical manifestations and renal pathological features in patients with Fabry's disease

[Investigation of multiple organ involvement in Fabry disease].

Fabry's disease: clinical, pathologic and biochemical manifestations in two Chinese males

Clinicopathological and genetic feathers of 14 Fabry nephropathy patients

Clinical features, genetic variations and enzyme replacement therapy in five Chinese patients with Fabry disease

Evolution of renal pathology in Fabry disease

Fabry disease: baseline clinical and pathological characteristics in a cohort of 83 Chinese cases

Report of a pedigree with Fabry disease and review of literature

Novel GLA gene mutations in two Chinese families with classic Fabry disease

Fabry Disease: Renal Biopsy-Proven Cases from China

[Two cases of heterozygous Fabry disease]

Diffuse Thin Glomerular Basement Membrane in Association with Fabry Disease in A Chinese Female Patient

Evaluation of vascular function in patients with Fabry disease

Overexpression of VEGFα as a biomarker of endothelial dysfunction in aortic tissue of α-GAL-Tg/KO mice and its upregulation in the serum of patients with Fabry's disease

Clinic-Pathologic Features and Renal Outcome of Fabry Disease: Data from a Chinese Cohort.

[A Boy with Fabry Disease with the Onset at the Age of Four].

A Female Patient of Fabry Disease Complicated with Thin Basement Membrane Nephropathy and Investigation of the Kindred

Study of ultrastructural pathology of renal Fabry disease

[Clinical analysis of 10 patients with Fabry disease]

Clinical and pathological characteristics of Fabry disease combined with IgA nephropathy in Chinese patients